RED PILL (RPILL) is a pharmaceutical company that manufactures and sells a variety of over-the-counter and prescription drugs. The company has a customer support number and headquarters in the United States.
RED PILL (RPILL) phone number.
RPILL phone number is a free phone number provided by Reverse Phone. If you want to find out who owns this phone number, you can use the Reverse Phone search tool.
RED PILL (RPILL) support.
RPILL is a new signaling protocol that enables communication between different components of a smart pill system. It enables the Pill application on a mobile device to communicate with the Pill controller on a wearable device, and vice versa. This enables the Pill application to monitor and control the functionality of the wearable device, and to provide relevant health information to the user.
RED PILL (RPILL) customer care.
If you have any questions or concerns about your RPILL order, please contact our customer care team. We are available 24/7 to help you with whatever needs you might have. You can reach us by calling 1-866-987-4357 or by using our contact form.
What is RED PILL (RPILL)?
The term " RED PILL " is often used to describe a secret knowledge or understanding that someone has that alters the way they see the world. The term is often used in reference to the novel and movie The Matrix .
RED PILL (RPILL) headquarters.
RPILL is a pharmaceutical company headquartered in Philadelphia, Pennsylvania. The company specializes in the development and commercialization of novel therapeutics for chronic diseases.
RPILL was founded in 2003 by Robert Langer and Andrew Feld. The company's initial focus was the development and commercialization of small molecule drugs for the treatment of cardiovascular diseases. In 2006, RPILL acquired the rights to develop and commercialize a new class of medications known as angiotensin converting enzyme inhibitors (ACE inhibitors). The company subsequently developed and launched the first ACE inhibitor, telmisartan, in 2011. In 2013, RPILL acquired the rights to develop and commercialize a new class of medications known as statins. The company subsequently developed and launched the first statin, atorvastatin, in 2015. In 2017, RPILL acquired the rights to develop and commercialize a new class of medications known as cannabinoid receptor type 1 (CB1) receptor antagonists. The company subsequently developed and launched the first CB1 receptor antagonist, nabilone, in 2018.
RPILL has partnered with several healthcare providers to develop and commercialize its drugs. These partners include AstraZeneca, Bayer, Eli Lilly, Janssen Pharmaceuticals, and Merck. RPILL has also partnered with several research institutions to develop new drugs. These institutions include the Massachusetts Institute of Technology (MIT) and the University of Pennsylvania.